Crossmark

Renogrit selectively protects against cisplatin-induced injury in human renal tubular cells and in Caenorhabditis elegans by harmonizing apoptosis and mitophagy

Crossref DOI link: https://doi.org/10.1038/s41598-024-69797-3

Published Online: 2024-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Balkrishna, Acharya

Gohel, Vivek

Pathak, Nishit

Joshi, Monali

Singh, Rani

Kumari, Ankita

Dev, Rishabh

Varshney, Anurag
License Information

Text and Data Mining valid from 2024-08-21

Version of Record valid from 2024-08-21
More Information

Article History

Received: 22 November 2023

Accepted: 8 August 2024

First Online: 21 August 2024

Competing interests

: The test formulation (Renogrit) was provided by Divya Pharmacy, Haridwar, Uttarakhand, India. Renogrit is a marketed medicinal product of Divya Pharmacy, Haridwar, India. AB is an honorary trustee in Divya Yog Mandir Trust, which governs Divya Pharmacy, Haridwar. In addition, he holds an honorary managerial position in Patanjali Ayurved Ltd, Haridwar, India. Divya Pharmacy, Haridwar and Patanjali Ayurved Ltd. Haridwar manufacture and sell many herbal medicinal products. Other than providing the test formulation (Renogrit), Divya Pharmacy was not involved in any aspect of the research reported in this study. All other authors have declared no competing interests.

Document is current

Any future updates will be listed below